Anthony W Tolcher

Summary

Publications

  1. pmc Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    A W Tolcher
    South Texas Accelerated Research Therapeutics START, Center for Cancer Care, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 70:305-13. 2012
  2. ncbi Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, 4383 Medical Dr, 4th Floor, San Antonio, TX 78229, USA
    J Clin Oncol 30:2348-53. 2012
  3. doi A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
    A W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
    Ann Oncol 23:968-73. 2012
  4. doi Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    J Clin Oncol 26:5198-203. 2008
  5. ncbi Stable disease is a valid end point in clinical trials
    Anthony W Tolcher
    START South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    Cancer J 15:374-8. 2009
  6. doi Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    J Clin Oncol 27:5800-7. 2009
  7. pmc A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Anthony W Tolcher
    START South Texas Accelerated Research Therapeutics, 4319 Medical Drive, Suite 205, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 67:751-64. 2011
  8. doi Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, Texas 78229, USA
    Clin Cancer Res 17:363-71. 2011
  9. ncbi The evolution of phase I trials in cancer medicine: a critical review of the last decade
    Anthony W Tolcher
    Breast Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    Chin J Cancer 30:815-20. 2011
  10. doi Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009

Detail Information

Publications50

  1. pmc Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
    A W Tolcher
    South Texas Accelerated Research Therapeutics START, Center for Cancer Care, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 70:305-13. 2012
    ..This open-label, single-arm phase 1b study was conducted to assess the effect of AA and abiraterone on the QT interval...
  2. ncbi Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, 4383 Medical Dr, 4th Floor, San Antonio, TX 78229, USA
    J Clin Oncol 30:2348-53. 2012
    ....
  3. doi A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
    A W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
    Ann Oncol 23:968-73. 2012
    ..This study was conducted to determine the activity of YM155 in patients with castration-resistant prostate cancer (CRPC) who received prior taxane therapy...
  4. doi Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    J Clin Oncol 26:5198-203. 2008
    ..To determine the maximum-tolerated dose (MTD) and assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of YM155, a small-molecule inhibitor of survivin...
  5. ncbi Stable disease is a valid end point in clinical trials
    Anthony W Tolcher
    START South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    Cancer J 15:374-8. 2009
    ....
  6. doi Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    J Clin Oncol 27:5800-7. 2009
    ..To determine the maximum-tolerated dose (MTD) and to assess the safety, pharmacokinetics, and evidence of antitumor activity of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 (IGF-1R)...
  7. pmc A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Anthony W Tolcher
    START South Texas Accelerated Research Therapeutics, 4319 Medical Drive, Suite 205, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 67:751-64. 2011
    ..To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer...
  8. doi Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics, START Center for Cancer Care, San Antonio, Texas 78229, USA
    Clin Cancer Res 17:363-71. 2011
    ....
  9. ncbi The evolution of phase I trials in cancer medicine: a critical review of the last decade
    Anthony W Tolcher
    Breast Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX 78229, USA
    Chin J Cancer 30:815-20. 2011
    ....
  10. doi Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
    Chia Chi Lin
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 63:1065-71. 2009
    ....
  11. doi Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies
    Chia Chi Lin
    The Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 65:167-75. 2009
    ....
  12. ncbi Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
    ..This provided the rationale for the three-times weekly treatment explored in this protocol...
  13. doi Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 15:723-30. 2009
    ..v. infusion every 3 weeks. The study also sought to determine the maximum tolerated dose and the recommended dose, to describe the pharmacokinetic (PK) behavior of the compound, and to seek preliminary evidence of anticancer activity...
  14. doi Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 15:3866-71. 2009
    ..The study aimed to assess the pharmacokinetic behavior of satraplatin under fasted and fed conditions, and its safety and preliminary antitumor activity in adults with advanced solid tumors...
  15. doi Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors
    Quincy Chu
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 16:2656-65. 2010
    ..The study also sought to determine the maximum tolerated dose (MTD) level on this schedule, as well as to recommend doses for disease-directed studies...
  16. ncbi A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 11:3854-61. 2005
    ....
  17. doi Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
    Monica M Mita
    Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center, San Antonio, TX, USA
    J Clin Oncol 26:361-7. 2008
    ....
  18. ncbi Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
    Chris H Takimoto
    Institute for Drug Development at the Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas 78245 3217, USA
    Clin Cancer Res 13:2675-83. 2007
    ..Pemetrexed plasma pharmacokinetics were evaluated for cycle 1...
  19. ncbi Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 12:7406-13. 2006
    ....
  20. ncbi A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 59:165-74. 2007
    ....
  21. ncbi A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies
    Garry H Schwartz
    Brooke Army Medical Center, San Antonio, TX, USA
    Invest New Drugs 22:437-48. 2004
    ....
  22. ncbi A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:5048-57. 2004
    ....
  23. ncbi Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired renal function...
  24. ncbi Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 21:211-22. 2003
    ..v.) once every 3 weeks and to seek evidence of antitumor activity...
  25. ncbi A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
    Mitchell A Garrison
    Brooke Army Medical Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2527-37. 2003
    ..The MTD was defined for both minimally pretreated (MP) and heavily pretreated (HP) patients as the highest dose level at which the incidence of dose-limiting toxicity does not exceed 20%...
  26. ncbi ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 10:7555-65. 2004
    ....
  27. pmc Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
    Amita Patnaik
    START South Texas Accelerated Research Therapeutics, 4383 Medical Drive, Suite 4021, San Antonio, TX 78229 3307, USA
    Cancer Chemother Pharmacol 71:1499-506. 2013
    ..This study evaluated the tolerability, pharmacokinetics, and preliminary antitumor activity of EZN-2208, a water-soluble poly(ethylene) glycol conjugate of SN38...
  28. ncbi Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 14:7947-55. 2008
    ..To evaluate the safety and describe the pharmacokinetic profile of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, in combination with cisplatin (CDDP) in adults with advanced solid tumors...
  29. ncbi Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA
    Clin Cancer Res 11:8728-36. 2005
    ..Major toxicologic and pharmacologic differences between the two sequences of drug administration were also assessed...
  30. ncbi Novel apoptosis inducing agents in cancer therapy
    Monica Mita
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, USA
    Curr Probl Cancer 29:8-32. 2005
  31. ncbi Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 24:2052-8. 2006
    ....
  32. ncbi Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USAS
    J Clin Oncol 25:1390-5. 2007
    ....
  33. ncbi A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
    Anthony W Tolcher
    South Texas Accelerated Research Therapeutics START, LLC, San Antonio, TX, USA
    Cancer Chemother Pharmacol 73:363-71. 2014
    ..Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100...
  34. pmc Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, TX, USA
    Clin Cancer Res 14:7924-9. 2008
    ....
  35. ncbi Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 10:7112-20. 2004
    ....
  36. ncbi A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor
    Desiree Hao
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2465-71. 2003
    ..The purpose of this study was to assess the feasibility and characterize the pharmacokinetics of squalamine administered as a continuous i.v. infusion daily for 5 days every 3 weeks...
  37. pmc The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Breast Cancer Res 5:154-9. 2003
    ..It is hoped that these studies will support the identification of the molecules driving a tumor's growth, and the selection of the appropriate combination of targeted agents in the near future...
  38. ncbi The role of mTOR inhibitors for treatment of sarcomas
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78230, USA
    Curr Oncol Rep 9:316-22. 2007
    ..This article discusses preliminary results from clinical trials in patients with advanced or metastatic sarcoma as well as future perspectives...
  39. doi A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA
    Cancer Chemother Pharmacol 68:959-70. 2011
    ..This study determined the safety, pharmacokinetics, and acute anti-vascular effects of MN-029...
  40. ncbi Technology insight: cytotoxic drug immunoconjugates for cancer therapy
    Alejandro D Ricart
    Institute for Drug Development, University of Texas Health Science Center, Suite Z418, 7979 Wurzbach Road, San Antonio, TX 78229, USA
    Nat Clin Pract Oncol 4:245-55. 2007
    ..This Review examines optimal design, the lessons learned from clinical immunoconjugate development, and the promising agents in early preclinical/clinical development for the treatment of cancer...
  41. ncbi Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma
    Johann S de Bono
    Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Semin Oncol 30:79-92. 2003
    ..Randomized clinical studies investigating the clinical benefits of farnesyltransferase inhibition, with or without a taxane and trastuzumab, in patients with treatment-naive HER2-positive metastatic breast carcinoma are now warranted...
  42. doi The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
    Toshio Shimizu
    South Texas Accelerated Research Therapeutics, START Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 18:2316-25. 2012
    ..This study evaluated the clinical relevance of the dual-targeting strategy involving PI3K/AKT/mTOR and RAF/MEK/ERK pathways...
  43. ncbi Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides
    Anthony W Tolcher
    University of Texas Health Sciences Center, San Antonio, TX 78229, USA
    Clin Adv Hematol Oncol 3:635-42, 662. 2005
    ....
  44. ncbi Regulators of apoptosis as anticancer targets
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Hematol Oncol Clin North Am 16:1255-67. 2002
    ..With specific agents such as oblimersan sodium in randomized "pivotal" studies, and agents targeting the TRAIL receptor-family recently entering early clinical study, cautious optimism is warranted...
  45. ncbi A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, TX, USA
    J Clin Oncol 21:148-57. 2003
    ..The study also sought to determine the maximum-tolerated dose (MTD) of PEG-CPT, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  46. ncbi Management of high risk metastatic prostate cancer: the case for novel therapies
    Timothy C Brand
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Urol 176:S76-80; discussion S81-2. 2006
    ....
  47. ncbi Novel therapeutic molecular targets for prostate cancer: the mTOR signaling pathway and epidermal growth factor receptor
    Anthony W Tolcher
    Director Clinical Research, Institute for Drug Development Cancer Therapy and Research Center, San Antonio, Texas, USA
    J Urol 171:S41-3; discussion S44. 2004
    ..The scientific rationale and existing evidence for the use of novel molecular targets in the chemoprevention of cancer are reviewed, with special attention to prostate cancer...
  48. ncbi New therapeutic strategies for prostate cancer: reasons for optimism and reflection
    Anthony W Tolcher
    Cancer Therapy and Research Center, San Antonio, TX, USA
    Invest New Drugs 20:143-4. 2002
  49. ncbi First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Texas 78229, USA
    J Urol 171:S3-4. 2004
  50. ncbi Development of novel alkylating drugs as anticancer agents
    Elzbieta Izbicka
    Cancer Therapy and Research Center, The Institute for Drug Development, 14960 Omicron Drive, San Antonio, TX 78245, USA
    Curr Opin Investig Drugs 5:587-91. 2004
    ....